398 related articles for article (PubMed ID: 16407371)
1. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
[TBL] [Abstract][Full Text] [Related]
2. PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.
Jia NL; Fei EK; Ying Z; Wang HF; Wang GH
Neurosci Bull; 2008 Aug; 24(4):201-8. PubMed ID: 18668148
[TBL] [Abstract][Full Text] [Related]
3. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
4. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3.
Haacke A; Hartl FU; Breuer P
J Biol Chem; 2007 Jun; 282(26):18851-6. PubMed ID: 17488727
[TBL] [Abstract][Full Text] [Related]
5. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
6. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
8. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
9. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
10. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
11. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
[TBL] [Abstract][Full Text] [Related]
12. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.
Jung J; Xu K; Lessing D; Bonini NM
Hum Mol Genet; 2009 Dec; 18(24):4843-52. PubMed ID: 19783548
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model.
Bonanomi M; Natalello A; Visentin C; Pastori V; Penco A; Cornelli G; Colombo G; Malabarba MG; Doglia SM; Relini A; Regonesi ME; Tortora P
Hum Mol Genet; 2014 Dec; 23(24):6542-52. PubMed ID: 25030034
[TBL] [Abstract][Full Text] [Related]
14. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
15. A novel nuclear DnaJ protein, DNAJC8, can suppress the formation of spinocerebellar ataxia 3 polyglutamine aggregation in a J-domain independent manner.
Ito N; Kamiguchi K; Nakanishi K; Sokolovskya A; Hirohashi Y; Tamura Y; Murai A; Yamamoto E; Kanaseki T; Tsukahara T; Kochin V; Chiba S; Shimohama S; Sato N; Torigoe T
Biochem Biophys Res Commun; 2016 Jun; 474(4):626-633. PubMed ID: 27133716
[TBL] [Abstract][Full Text] [Related]
16. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
17. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
18. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
19. Co-chaperone CHIP promotes aggregation of ataxin-1.
Choi JY; Ryu JH; Kim HS; Park SG; Bae KH; Kang S; Myung PK; Cho S; Park BC; Lee DH
Mol Cell Neurosci; 2007 Jan; 34(1):69-79. PubMed ID: 17127076
[TBL] [Abstract][Full Text] [Related]
20. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.
Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V
J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
